Back to All Studies

Immune-mediated hemolytic anemia (IMHA) is a serious blood disorder with a high mortality rate in dogs. Despite years of research and advances in the diagnosis, few effective treatment options are available for IMHA. Researchers will evaluate a new drug, currently used to treat similar diseases in people, as a potential new canine IMHA treatment. While the underlying causes of IMHA and the human diseases differ, the target biological mechanisms are similar. This study will determine the drug's safety and dosing for dogs as a precursor for future clinical trials that could help transform how we treat dogs with this deadly disease.

Study ID
Study Status
Start Date
Grant amount awarded
Grant recipient
Cornell University
Study country
United States
Erica L. Behling-Kelly, DVM, PhD
Study category
Hematology (Blood)